Physician profile
Luis Daniel Rojas
NPI 1508247644
$308,528.01
in general payments reported to CMS, 2019-2025
22 companies · $77K in 2025
The $77K reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $847 · 2020: $221 · 2021: $6,281 · 2022: $56K · 2023: $103K · 2024: $65K · 2025: $77K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $171K · Travel and Lodging: $40K · Consulting Fee: $21K · Food and Beverage: $13K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $171,375.00 |
| Travel and Lodging | $40,001.12 |
| Consulting Fee | $20,525.00 |
| Food and Beverage | $13,315.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $305,222.60 | 2019-2025 | Acuvue, Axert |
| Alcon Vision LLC | $421.57 | 2019-2024 | Total30 |
| Lkc Technologies, INC. | $382.42 | 2023-2025 | |
| Biotissue Holdings INC. | $306.18 | 2023-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $280.51 | 2019-2020 | |
| Oyster Point Pharma, INC. | $230.35 | 2022-2025 | Tyrvaya, Ryzumvi |
| Tarsus Pharmaceuticals, INC. | $192.50 | 2024-2025 | Xdemvy |
| Maculogix, INC. | $180.85 | 2021 | |
| Sun Pharmaceutical Industries INC. | $167.68 | 2023-2025 | Cequa |
| Amgen INC. | $154.68 | 2025 | Tepezza |
| Harrow Eye, LLC | $140.64 | 2024-2025 | Vevye |
| Dompe US, INC. | $122.13 | 2024 | Oxervate |
| Genzyme Corporation | $121.95 | 2019 | |
| Novartis Pharmaceuticals Corporation | $116.54 | 2019 | |
| Coopervision INC. | $108.81 | 2019-2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $96.92 | 2022 | |
| Sight Sciences, INC. | $74.63 | 2025 | Tearcare System |
| Allergan, INC. | $69.97 | 2021-2022 | |
| Topcon Healthcare, INC. | $43.07 | 2024 | |
| Bausch & Lomb Americas INC. | $37.79 | 2024 | Miebo, Infuse |
| Shire North American Group INC | $34.62 | 2019 | |
| Shionogi INC | $21.60 | 2023 | Fetroja |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Rojas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.